Eggshell Research Institute
蛋壳研究院
elsewhere's corpus does not cover Eggshell Research Institute as a subject in its own right. The only mentions in the bundle are background references in two BlueRun Ventures articles about a peptide-drug industry forum, where Eggshell Research Institute (蛋壳研究院) is listed as a co-organizer alongside VB100, Artery Network, and Artery Orange . No founding date, leadership, scope of work, or institutional profile is provided.
AI-generated — may contain errors, please verify.
Coverage
The Trillion-Yuan Blueprint for Peptide Drugs: From Diabetes Medication to Weight-Loss Wonder | BlueRun Ventures Biotech Forum Recap
From Pharmaceuticals to Consumer Goods: A Wave of Value Creation
BlueRun Ventures Portfolio Companies Named to 2024 Future Healthcare 100 List
Continuously searching for next-generation biotech companies that align with industry logic
With a Market Worth Hundreds of Billions, When Will Peptide Drugs Become the Next Blockbuster? | BlueRun Ventures × VBData Forum Now Open for Registration
Where Does the Hot Peptide Market Go From Here?
Into the Dalton Venture Family | Leveraging Two Technology Platforms — Low-Temperature Plasma and Radiofrequency Ablation — Favamed Charts a Platform Strategy
As of today, Fangrun Medical and its subsidiaries have secured 19 NMPA registrations. Its products are now used in over 1,200 hospitals across China, with successful exports to Europe and Southeast Asia, serving more than 100,000 patients annually.
Multiple BlueRun Ventures portfolio companies named to 2023 Future Healthcare 100 list
Standing by founders from 0 to 1 to redefine the future.
